

CITATION REPORT

List of articles citing

Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany

DOI: 10.1016/j.jval.2017.09.010
Value in Health, 2018, 21, 698-706.

Source: <https://exaly.com/paper-pdf/69744063/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
6	Health Technology Assessment Challenges in Oncology: 20 Years of Value in Health. <i>Value in Health</i> , 2019 , 22, 593-600	3.3	6
5	The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany. <i>Health Economics Review</i> , 2020 , 10, 7	2	1
4	Critical review of oncology clinical trial design under non-proportional hazards. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 162, 103350	7	2
3	Oncology from an HTA and Health Economic Perspective. <i>Recent Results in Cancer Research</i> , 2019 , 213, 25-38	1.5	2
2	Fooled by randomness. The misleading effect of treatment crossover in randomized trials of therapies with marginal treatment benefit.. <i>Cancer Investigation</i> , 2021 , 1-7	2.1	0
1	An Initial Injection and a Crossover Injection of Amniotic Suspension Allograft Following Failed Treatment with Hyaluronic Acid or Saline Are Equally Effective in the Treatment of Moderate Symptomatic Knee Osteoarthritis Over 12 Months. <i>Arthroscopy - Journal of Arthroscopic and Related Surgery</i> , 2022 ,	5.4	0